ANTIBACTERIAL PYRIDO(1,2,3-DE)-1,4-BENZOXAZINONE AGENTS

Abstract: This invention concerns novel benzoxazinone carboxylic acids having a novel dimethyl 1,2-dicarboxyethylene substituent and their use in treating bacterial infections in warm blooded animals and man. The compounds of this invention (Formula I) are readily prepared by conventional chemical reactions.

Description: A TIBACTERIAL PYRIDO(1,2,3-DE)-1, -BENZOXAZINONE AGENTS BACKGROUND OF THE INVENTION The present invention relates to new 2-[4-[6-carboxy-9-fluoro- 2,3-dihydro-7-oxo-7H-pyrido(l,2,3-de)-l,4-benzoxazin-10-yl]diaminyl]- 2-butendioic acid, 1,4 disubstituted esters useful as antibacterial agents. Ofloxacin and various analogs are known for their antibac¬ terial properties, however new antibacterials are continually sought especially those which exhibit both gram positive and gram negative activity. U.S. Patent 4,777,253 discloses various methods of producing the racemate and enantiomers of 9-fluoro-3-methyl-10-substituted amino-7- oxo-2,3-dihydro-7H-pyrido[l,2,3-de]-1,4-benzoxazine-6-carboxylic acid compounds. The preparation of various piperazinyl and 3-amino-l-pyr- rolidinyl naphthyridine derivatives, including 2-(4-(l-cyclopropyl-3- carboxy-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl)-2- butanedioic acid, 2-(4-(1-cyclopropyl-3-carboxyethyl-6-fluoro-1,4- dihydro-4-oxo-7-quinolinyl)-l-piperazinyl)-2-butanedioic acid, dimethyl ester, 2-(4-(l-ethyl-3-carboxy-6-fluoro-l,4-dihydro-4-oxo-7- quinolinyl)-l-piperazinyl)-2-butanedioic acid, and 2-(4-(l-ethyl-3- carboxyethyl-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl)- 2-butanedioic acid, dimethyl ester are disclosed in Japanese publica¬ tion 62-207258 (Chem. Abst. 108(5) :37868p) and Great Britain Patent Application 87-GB-002508. BRIEF DESCRIPTION OF THE INVENTION The present invention is directed toward new compounds useful as antibacterials or in the preparation of antibacterial compositions. The compound of the present invention is as shown in Formula I or therapeutically acceptable salts wherein: R is hydrogen or hydroxyl; R2 is hydrogen or methyl; R3 is hydrogen, halogen, amine or hydroxyl; R4, R5, Rg, R7 are independently hydrogen, hydroxyl, halogen, C -C alkyl, ethenyl, ethynyl, C3-C6 cycloalkyl, fluoromethyl, difluoromethyl, difluoroethyl, trifluoromethyl, hydroxymethyl, 0χ- C 8 alkoxy methyl, phenoxyπtethyl, C -C3 alkyl aminomethyl, C -C3 dialkyl aminomethyl, C -C 2 aryl > substituted aryl, heteroaryl or substituted heteroaryl containing at least one 0, N or S; Rg Is hydrogen, hydroxyl, a ine, C1-C4 alkoxy or aryloxy, -SH, Cχ-Cg thioalkyl or thioaryl; 9 is C -C alkyl, Cg-Cχ 2 aryl, alkylaryl, heteroaryl, -(CH2> n - Cθ2-(CH2) m -R-_χ, wherein R ι is hydrogen, hydroxyl, methyl^ alkyloxy, 5 aryloxy or an amine, n is 0-4 and m is 0-4; R 10 is hydrogen, -(C__3) 0j C2-C4 alkyl, Cg-C 12 aryl, alkylaryl, heteroaryl, or acetyl, where o is 0 or 1; _. R_2 is hydrogen CN, halogen, or R9; and Z is (CH 2 ) q where q is 0-2, CH-CH3 or C(CH 3 ) 2 . 0 t The dotted bonds indicate that the carbon atom having the R5 group can be bonded to either the nitrogen to form Formula la or the carbcp atom having the Rg group to form Formula lb. When the structure Is as depicted in Formula la then R o I s "(CH3) 0 where o is .0 and preferably, t Z is (CH2. π where q is 0. 15 Prefer*red compounds of the present invention include (E)-2-[4- [6-carboxy-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)- 1,4-benzoxazin-lθ-yl]-1-piperazinyl]-2-butendioic acid, 1,4-dimethyl ester _ (Compound- 1) and (E)-2-[4-[6-carboxyethyl-9-fluoro-2,3- dihydro-7-oxo-7H-pyrido(l , 2 , 3-de) -1 ,4-benzoxazin-10-yl] -1- 20 piperazinyl]-2-butendioic acid, 1,4-dimethyl ester (Compound 2). In another aspect, the present invention is a pharmaceutical composition containing an antibacterially effective amount of a compound or therapeutically acceptable salts thereof according to Formula I in admixture with a pharmaceutical carrier. The composi- 25 tion can contain from about 0.5 to about 90% by weight of such compound. The composition can be present in unit dose form of tab¬ lets, pills,, dragees-, capsules, ampules or suppositories. In yeϋ ι another aspect, the present invention is method for treating bacterial infection in animals including humans which 30 comprises administering an antibacterially effective amount of a compound or therapeutically acceptable salts thereof according to Formula I. In the method the compound can be administered orally or parenterally. DETAILED DESCRIPTION OF INVENTION 35 The presenf. invention relates to pyrido(l,2,3-de)-l,4- benzoxazinone carboxylic acids incorporating a novel 1,2-dicar- boxyethylene substitutent and antibacterial agents containing these compounds. The benzoxazinone compounds are structurally represented by Formula I, shown on the Formula Sheet, and includes therapeuti¬ cally acceptable salts thereof wherein Rx is hydrogen or hydroxyl; R 2 is hydrogen or methyl; R3 is hydrogen, halogen, amine or hydroxyl; R4, R5, Rg, R7 are independently hydrogen, hydroxyl, halogen, C -C alkyl, ethenyl, ethynyl, C3-C cycloalkyl, fluoromethyl, difluoro- methyl, difluoroethyl, trifluoromethyl, hydroxymethyl, Cχ-Cχg alkoxy methyl, phenoxy-methyl, C -C3 alkyl aminomethyl, C -C3 dialkyl aminomethyl, Cg-Cχ aryl, substituted aryl, heteroaryl or sub¬ stituted heteroaryl; Rg is hydrogen, hydroxyl, amine, C -C alkoxy or aryloxy, -SH, Cχ-Cg thioalkyl or thioaryl; R9 is C -C4 alkyl, Cg-C 2 aryl, alkylaryl, heteroaryl, -(CH2 n -C02-(CH2) m -Rχχ, wherein R is hydrogen, hydroxyl, methyl alkyloxy, aryloxy or an amine, n is 0-4 and m is 0-4; R ø is hydrogen, -(CH3) 0 C2-C4 alkyl, Cg-C 2 aryl, alkylaryl, heteroaryl, or acetyl, where o is 0 or 1; Rχ 2 is hydrogen CN, halogen, or R9; X is nitrogen or carbon substituted by fluorine; Y is nitrogen, a carbon substituted with hydrogen, hydroxyl, cyano, nitro, halogen, C -C alkyl, or an amine; and Z is (CH2) q where q is 0-2, CH-CH3 or C(CH 3 ) 2 . The dotted bonds indicate that the carbon atom having the R5 group can be bonded to either the nitrogen to form Formula la or the carbon atom having the Rg group to form Formula lb. When the structure is as depicted in Formula la then R o I s "(CH3) 0 where o is 0 and preferably, Z is (CH2) q where q is 0. Preferred compounds of Formula la are where R is hydroxy, R 2 is hydrogen or methyl, R3 is hydrogen or fluorine, R4, R5, Rg and R7 are hydrogen, Rg is methoxyl, R9 is a carbomethoxyl ester so as to form either the dimethylester of maleic or fumaric acid and R o is- (CH3) 0 where o is 0. Preferred compounds of Formula lb are when R is hydroxyl and R2 is hydrogen or methyl and R are hydrogen, Rg is O-CH3, R 9 is C(0)0CH 3 , X and Y are C(F) and Z is (CH 2 ) q where q is zero. Examples of "Cχ-Cχø alkyl" are one to ten carbon atoms such as methyl, ethyl, propyl, butyl, etc. and isomeric forms thereof. The "C2-C4 alkylenes" are ethylene, propylene and 1 or 2-butylene and isomeric forms thereof. Examples of "C3-CX0 cycloalkyl" are cyclo- propyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. and "heterocyclo- alkyl"are cycloalkyl ring which contain at least one heteroatom such as oxygen, sulfur or nitrogen. Exa ples of "Cg.Cχ aryl" are compounds such as phenyl, o- naphfchyl, 0-naphthyl, m-methylphenyl, p-trifluoromethyIphenyl and the like. The aryl groups can also be substituted with one to 3 hydroxy, Cχ-C3 alkoxy, Cχ-C3 alkyl, trifluoromethyl, fluoro, chloro or bromo groups. Examples of "alkylaryl" are alkyl chains of one to eight carbon atoms and isomeric forms thereof which are substituted with aryl groups of 6 to 12 carbon atoms, for example, benzyl. Examples of "heteroaryls" are 6 to 12 carbon atom aryls which contain at least one heteroatom such as nitrogen, sulfur and oxygen. An "amine" is meant to Include primary, secondary and tertiary amines, preferably primary amine (NH ) _ "Halogen" is meant to include F, Cl, Br and I. "Therapeut¬ ically acceptable salts" are those compounds of Formula I wherein a carboxyl group is substituted with a counter ion such as Li, Na, K, Ca or other acceptable counter ions for carboxylic acids. A generic scheme for the preparation of the Formula la compounds is illustrated in Chart 1. A generic scheme for the preparation of the Formula lb compounds is illustrated in Chart 2. The compounds according to the invention have good actions against Gram-positive and Gram-negative bacteria, particularly against enterobacteriaceae. The effectiveness of the subject compounds on bacteria were obtained by performing a dip disk assay. The antibacterial activity of the compounds was determined by the disk-diffusion method. Paper disks (12.7 mm) were loaded with 0.05 ml of drug solution prepared at a concentration of 0.1 mcg/ml; the disks were allowed to air dry. They were then applied to the surface of microorganism-seeded agar assay " trays, which contained the bacterial strain Pseudomonas aeruginosa UC 95 (PA) , Escherichia coli UC 51 (EC) , Klebsiella pneumoniae UC 57 (KP) , Staphylococcus aureus UC 80 (SA) , Penicillium oxalicum UC 1268 (PO) , Streptococcus pyogenes UC 6055 (ST) , Bac- teroides fragilis UC 6513 (BF) , Candida albicans UC 1392 (CA) , Staphylococcus aureus UC 6685 (SR) , Staphylococcus epidermidis UC 719 (SE) , Streptococcus pneumoniae UC 9207 (SO) , Streptococcus faecalis UC 241 (SF), Serratica marcescens UC 6888 (SM) , Bordetella bronchi- septica UC 6481 (BR) or Clostridium perfringens UC 6509 (CP) . The assay trays were incubated overnight under aerobic condition to allow for the growth of the organisms. Zones of growth inhibition due to the action of the antibiotic were then measured to the nearest milli¬ meter. Formula la (Growth Inhibition at 0.1 mcg/ l fc Compound SA KP 1 (84318) . 27H 25 25 27 2 (85178) 24 25 25 27 PO _v_ SE CA 1 0 35 0 0 2 0 28 29 0 UK __£ so HE 1 30 30 25 24 2 26 26 25 24 J2E __E 1 16H 14 31 2 23 19 30 The results show that compounds 1 and 2, all of Formula la, cor¬ responding to Examples 1 and 2, below, have potent gram negative and positive activity. Comoound Cone KP SA ££ £& 1 1 mg/ml 30 26 26 31 1 0.1 mg/ml 26 23 24 20 Cipro 1 mg/ml 34 29 31 40 Cipro 0.1 mg/ml 32 27 30 38 Compounds of this invention can also be tested for in vitro antimicrobial activity using standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilu- tion as described in "Methods for Dilution Antimicrobial Susceptibil¬ ity Tests for Bacteria That Grow Aerobically" (MFT) published January 1983 by the National Committee for Clinical Laboratory Standards, 771 East Lancaster Avenue, Villanova, PA 19084, USA. Briefly, MIC values are. determined in unsupplemented Mueller Hinton Agar (MHA) . The * compounds tested are diluted serially into molten MHA at 47 * C. The agar is poured into petri dishes and allowed to harden. The various bacteria used for testing are grown overnight on MHA at 35 * C and 5 transferred to Tryptloase soy broth (TSB) until a turbidity of 0.5 McFarland standard Is obtained. The bacteria are diluted one to 20 in TSB and inoculated on the plates (1 μl using a Steers replicator) . The plates are incubated at 35"C for 20 hours and the MIC is read to ' be the lowest concentration of drug that completely inhibits visible 10 growth of the bacteria. The MIC test results of selected compounds of this invention are found in Tables I. The compounds according to the invention have a potent and broad antimicrobial efficacy. These properties make it possible to use , them as che otherapeutic active compounds in medicine and as sub- 15 stances fpr preserving inorganic and organic materials, in particular organic materials of all types, for example polymers, lubricants, dyes, fibers, leather, paper and wood, foodstuffs and water. The compounds according to the invention are active against Gram-negative and Gram-positive bacteria and bacterioid microorgan- 20 isms. Thus, diseases caused by these pathogens can be treated. The compounds according to the invention are particularly active against bacteria and bacterioid microorganisms. Thus, they are part¬ icularly well suited for the chemotherapy of local and systemic in¬ fections caused by these pathogens in medicine. 25 For example, local and/or systemic diseases caused by the fol¬ lowing pathogens or by mixtures of the following pathogens can be treated and/or prevented: Micrococcaceae, such as staphylococci, for example Staphylococcus aureua, Staph. Epidermidis, (Staph. - Staphyl¬ 3r ococcus); Lactobacteriaceae, such as streptococci, for example Strep- 30 tococcus pyogenes, α- and .-haemolytic streptococci, non (7-) haemo- lytic streptococci, enterococci and Dlplococcus pneumoniae (pneumo- cocci) .(Str. - Streptococcus); Enterobacteriaceae, such as encherich- iae bacteria of the coli group; encherichia bacteria, for example Escherichia coli, enterobacter bacteria, for example aerogenes, E. 35 cloacae, Klebsiella bacteria, for example K. pneumoniae, serratin, * * • for example Serratia marcescens (E. - Enterobacter) (K. - Klebsi¬ ella), proteae bacteria of the proteus groups; proteus, for example Proteus vulgaris, Pr. organii, Pr. rettgeri and Pr. mirabilis (Pr. - Proteus) ; pseudomonadaceae, such as pseudo onas bacteria, for example Pseudomonas aeruginosa (PS. - Pseudomonas); bacteroidaceae, such as bacteroides bacteria, for example Bacteroides fragilis (B. - Bacter- oides); mycoplasma, for example Mycoplasma pneumonia. The present invention includes pharmaceutical preparations which in addition to non-toxic, inert pharmaceutically suitable excepients contain one or more compounds according to the invention or which consist of one or more active compounds according to the invention, ' and processes for the production of these preparations. The present invention also Includes pharmaceutical preparations in dosage units. This means that the preparations are in the form of individual parts, for example tablets, dragees, capsules, pills, sup¬ positories and ampoules, of which the content of active substance corresponds to a fraction or a multiple of an individual dose. An individual dose preferably contains the amount of active compound which is given in one administration and which usually corresponds to a whole, a half or a third or a quarter of a daily dose. By non-toxic, inert pharmaceutically suitable excipients there are solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds. Preferred pharmaceutical preparations are tablets, dragees, capsules, pills, granules, suppositories, solu¬ tions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays. Tablets, dragees, capsules, pills and granules can contain the active compound or compounds alongside the customary excipients such as (a) fillers and extenders, for example starches, lactose, sucrose, glucose, mannitol and silica, (b) binders, for example carboxymeth l- cellulose, alginates, gelatine and polyvinylpyrrolidone, (c) humec- tants, for example glycerine, (d) disintegrating agents, for example agar-agar, calcium carbonate and sodium carbonate, (e) solution re- tarders, for example paraffin, and (f) absorption accelerators, for example quaternary ammonium compound (g) wetting agents, for example cetyl alcohol or glycerine monostearate, (h) adsorbents, for example kaolin and bentonite, and (i) lubricants, for example talc, calcium stearate and magnesium stearate and solid polyethylene glycols, or mixtures of the substances listed under (a) to (i) . The tablets, dragees, capsules, pills and granules can be pro¬ vided with the customary coatings and shells, optionally containing opacifying agents, and can also be of such composition that they release the active compound or compounds only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner, examples of embedding compositions which can be used being polymeric substances and waxes. The active compound or compounds, optionally together with one or more of the above mentioned excipients, can also be in a micro- encapsulated form. Suppositories can contain, in addition to the active compound or compounds, the customary water-soluble or water-insoluble excipients, for example polyethylene glycols, fats, for example cacao fat, and higher esters (for example Cχ4-alcohol with Cχg-fatty acid) or mix¬ tures of these substances. Ointments, pastes, creams and gels can contain the customary excipients in addition to the active compound or compounds, for example animal and vegetable fats, waxes, paraffins, starch, traga- canth, cellulose derivatives, polyethylene glycols, silicones, ben- tonites, silica, talc and zinc oxide or mixtures of these substances. Powders and sprays can contain the customary excipients in addition to the active compound or compounds, for example lactose, talc, silica, aluminum hydroxide, calcium silicate and polyamide powders or mixtures of these substances. Sprays can additionally contain the customary propellents, for example chlorofluorohydro- carbons. Solutions and emulsions can contain the customary excipients in addition to the active compound or compounds, such as solvents, solu- bilising agents and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylfor- mamide, oils, especially cottonseed oil, groundnut oil, maize germ oil, olive oil, castor oil and sesame oil, glycerine, glycerine- formal, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances. For parenteral administration, the solutions and emulsions can be in a sterile form which is isotonic with blood. Suspensions can contain the customary excipients in addition to the active compound or compounds, such as liquid diluents, for exam¬ ple water, ethyl alcohol or propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances. The formulation forms mentioned can also contain dyestuffs, preservatives and additives which improve the odour and flavour, for example peppermint oil and eucalyptus oil, and sweeteners, for exam¬ ple saccharin. The therapeutically active compounds should preferably be pre- sent in the above mentioned pharmaceutical preparations in a concen¬ tration of about 0.1 to 99.5, preferably of about 0.5 to 95, percent by weight of the total mixture. The above mentioned pharmaceutical preparations can also contain other pharmaceutical active compounds in addition to the active com- pounds according to the invention. The above mentioned pharmaceutical preparations are manufactured in the usual manner according to known methods, such as by mixing the active compound or compounds with the excipient or excipients. The active compounds or the pharmaceutical preparations can be administered locally, orally, parenterally, intraperitoneally and/or rectally, preferably orally or parenterally, such as intravenously or intramuscularly. In general, it has proved advantageous in medicine to administer the active compound or compounds in total amounts of about 0.5 to about 50, preferably 1 to 30, especially preferably 1-20 mg/kg of body weight, orally or parenterally, every 24 hours, optionally in the form of several individual administrations, in order to achieve the desired results. An individual administration contains the active compound or the active compounds preferably in amounts of about 1 to about 250, especially of 3 to 60, mg/kg of body weight. However, it can be necessary to deviate from the dosages mentioned and in particular to do so as a function of the nature and body weight of the subject to be treated, the nature and the severity of the illness, the nature of the preparation and of the administration of the medicine, and the time or interval over which the administra¬ tion takes place. Thus it can suffice in some cases to manage with less than the above mentioned amount of active comp und whilst in other cases the above mentioned amount of active compound muyt be -10- exceeded. The particular required optimum dosage and the type of administration of the active compounds can easily be decided by anyone skilled in the art, on the basis of his expert knowledge. The compounds of Formula I according to this invention may be provided as pharmaceutically acceptable acid addition and base salts wherein the anion or cation, respectively, does not contribute sig¬ nificantly to the toxicity of the salt and which salts are compatible with the standard and conventional pharmaceutically acceptable carriers and other conventional adjuvants and excipients customarily employed in producing pharmaceutical compositions adapted for oral or parenteral administration. The acid addition salts are formed by conventional techniques involving reaction of compounds of Formula I with mineral acids such as, for example, hydrochloric acid, hydrobro- mic acid, phosphoric acid, and sulfuric acid, and with organic carb- oxylic and sulfonic acids such as, for example, aspartic acid, glut- amic acid* . galaeturonic acid, gluconic acid, acetic acid, citric acid, maleic acid, succinic acid, benzoic acid, tartaric acid, ascorbic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxy- ethanesulfonic acid., p-toluenesulfonic acid, and the like. It is to be understood that the formulas herein representing the various compounds according to the invention are intended to embrace all optical isomers, as well as racemic mixtures thereof, within the scope of the given formulas unless otherwise indicated. In another aspect, as is mentioned above, this invention is a pharmaceutical composition comprising an antibacterially effective amount of a compound of Formula I above. In still another aspect, this invention is a method of combat¬ ting hacterial Infection in warm-blooded animals comprising adminis¬ tering to said animals an antibacterially effective amount of a com- pound of Formula I err of a pharmaceutical composition thereof. Pharmaceutically acceptable base salts are formed by conven¬ tional techniques involving reaction of the compounds of Formula I with alkali (Na,K) and alkaline earth (Ca, Ba, Zn, Mn) metal bases, more preferably with alkali metal bases such as, for example, dilute - solutions of sodium hydroxide and potassium carbonate. Also, pharma¬ ceutically accept£_ble- base salts are formed by conventional tech¬ niques involving reaction with amines such as, for example, triethyl- amine, dibenzylaπtlne, , triethanola ine, ethanolamine, N,N'-dibenzyl- ethylenediamine, procaine and equivalent amines. The new compounds can be utilized as feedstuff. Example 1 Preparation of (E)-2-[4-[6-carboxy-9-fluoro-2,3- dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)-l,4- benzoxazin-10-yl]-l-piperazinyl]-2-butendioic acid, 1,4-dimethyl ester (Compound #1) The starting material 9-fluoro-3-methyl-10-(l-piperazinyl)-7- oxo-2,3-dihydro-7H-pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid ' is disclosed in Chem. Pharm. Bull., 32:4907 (1984) by I. Hayakawa et al. and can be prepared in accordance with Procedure 1. Dimethyl acetylene dicarboxylate (55 ~ L, 0.45 mmol) is added to a stirring solution of 9-fluoro-3-methyl-10-(l-piperazinyl)-7-oxo- 2,3-dihydro-7H-pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid (0.15 g, 0.45 mmol) in dimethyl formamide (5 ml, DMF) . The solution is stirred at room temperature for 8 hours, the solvent evaporated off under a stream of nitrogen. The residue is flash chromatographed over silica gel (15 g, 0.5% acetone in 10% methanol/methylene chloride) to yield 0.13 g of Compound #1 (m.p. 235-238 β C). Example 2 Preparation of (E)-2-[4-[6-carboxyethyl-9-fluoro-2,3- dihydro-7-oxo-7H-pyrido(l,2,3-de)-l,4-benzoxazin-10- yl]-1-piperazinyl] -2-butendioic acid, 1,4-dimethyl ester (Compound #2) The starting material 9-fluoro-10-(l-piperazinyl)-7-oxo-2,3- dihydro-7H-pyrido[l,2,3-de]-1,4-benzoxazine-6-carboxylic acid ethyl ester is disclosed in Chem. Pharm. Bull. 32:4907 (1984) by I. Hayakawa et al. and can be prepared in accordance with Procedure 2. 9-fluoro-10- (l-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3- de]-l,4-benzoxazine-6-carboxylic acid ethyl ester (335 mg, 0.93 mmol) is dissolved in chloroform (25 ml) and dimethyl acetylene dicarboxy- late (150 μl , 1.2 mmol) is added. The mixture is stirred at 23°C for 30 min, then concentrated and recrystallized from ethyl acetate/- Skellysolve B to give the malonate ester as a white solid (421 mg, 90%). Of this product, (200 mg, 0.40 mmol) is dissolved in tetra- hydrofuran (10 ml) and 1.6 equivalents of potassium triethyl silano- late (85 mg, 0.66 mmol) is added at 23°C. The mixture is stirred for 1 h. Turning from a deep red color to pale, the solvent is then evaporated to give an orange oil which is chromatographed over Si0 2 slurry with methylene chloride/ethanol/acetic acid (89:10:1) to give 140 mg of white solid (74%). The Lilly compound is recrystallized from methanol as a white solid (104 mg) m.p. 271-3 # C dec. Example 3 Preparation of (E)-2-[4-[6-carboxy-9-fluoro-2,3- dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)-l,4- benzoxazine-10-yl] -3-aminopyrrolIdinyl]-2-butendioic acid, 1,4-dimethyl ester (Compound #3) [13 of Chart 3 where R 2 - CH3 and R3 - H] The starting material 9-fluoro-3-methyl-10(3-amino-l-pyr- rolidinyl) -7-OXO-2,3-dihydro-7H-pyrido[1,2,3-de]-l,4-benzoxazine-6- carboxylic acid is disclosed in Chem. Pharm. Bull. 32:4907 (1984) by I. Hayakawa et al. and can be prepared in accordance with Procedure 1, making non-critical modifications, and utilizing the appropriate starting material. Dimethyl acetyl dicarbox late (0.19 ml, 1.5 mol) is added to a stirring solution of 9-fluoro-3-methyl-10-(3-amino-l-pyrrolidinyl)-7- oxo-2,3-dihydro-7H-pyrido[l,2,3-de]-1,4-benzoxazine-6-carboxylic acid (0.52 g, 1.5 mmol) in dimethylformamide (13 ml). The solution is stirred at room temperature for 3 days, the solvent evaporated off under a stream of nitrogen. The residue is chromatographed over silanized silica gel (80 g, chloroform) to yield 0.31 g of compound #3 which is recrystallized from methylene chloride/hexane (m.p. 145- 152 β C). Procedure 1 Preparation of 9-fluoro-3-methyl-10-(l-piperazinyl)-7- oxo-2,3-dihydro-7H-pyrido[l,2,3-de]-l,4-benzoxazine-6- carboxylic acid, ethyl ester Part A:- Triethylorthoformate (15.8 g, 106 mmol) is added to a solution of α,α-DIoxo-2,3,4,5.-tetrafluoro-benzenebutanoic acid, ethyl ester (50 g, 0.19 mmol) in acetic anhydride (80ml). After refluxing for 5 hours, the solvent is evaporated and azeotroped with toluene twice in vacuo at 60 β C to yield 67 g of 2,3,4,5-tetrafluoro-α- [(ethoxy)- methylene] -/3-oxo-benzenepropanoic acid, ethyl ester. The product is stored at -20 β C and can be use in subsequent steps without further purificiation. Part B: D,L-Alanol (2.34 g, 31.2 mmol) is added to a solution of 2,3,4,5-tetrafluoro-α-[(ethoxy)methylene]-3-oxo-benzeneproρanoic acid, ethyl ester (10.0 g, 31.2 mmol of Part A) in methylene chloride (50 ml). After stirring for 22 h, the solvent is evaporated in vacuo and the residue flash chromatographed over silica gel (400 g, 5 x 40 ml fractions of 50% ethyl acetate/methylene chloride) to yield 8.54 g of 2,3,4,5-tetrafluoro-α-[[(2-hydroxy-1-methylethyl)amino]methylene]- .-oxo-benzenepropanoic acid, ethyl ester. Part C: Sodium hydride (60% oil dispersion, 2.08 g, 53 mmol) is added to a solution of 2,3,4,5-tetrafluoro-α-[ [(2-hydroxy-l-methylethyl)- amino]methylene]-^-oxo-benzenepropanoic acid, ethyl ester (8.5 g, 24.3 mol, Part B) in tetrahydrofuran (165 ml) stirring at 0 β C. The ice bath is removed and the solution is stirred at ambient tempera¬ ture. After stirring for 6 h and evaporation of the solvent in vacuo, the residue is transferred to a separatory funnel with chloroform/water. Extraction with chloroform (3x) and drying the combined organic layers with magnesium sulfate affords 5.30 g of crude 9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7-pyrido(l,2,3-de)- 1,4-benzoxazine-6-carboxylic acid, ethyl ester. Flash chromatography over silica gel (500 g, 3% methanol/methyl- ene chloride, 40 ml fractions) to afford 3.30 g of 9,10-difluoro-2,3- dihydro-3-methyl-7-oxo-7-pyrido(l,2, 3-de)-1,4-benzoxazine-6-car¬ boxylic acid, ethyl ester (44%, fractions 31-50). Part D: 9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7-pyrido(l,2,3-de)- l,4-benzoxazine-6-carboxylic acid, ethyl ester (2.0 g, 6.5 mmol) is refluxed in 6N hydrochloric acid (HC1) (50 ml). After 8 h, the solvent is evaporated off under a stream of nitrogen. Trituration with hot ethanol affords 1.7 g (93%) of crystalline 9,10-difluoro- 2, 3-dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)-l,4-benzoxazine-6- carboxylic acid. Mp 320 β C. Part E: Piperazine (0.9 g, 10.5 mmol) is added to a solution of the difluoro acid 9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(- 1,2,3-de)-1, -benzoxazine-6-carboxylic acid (0.75 g, 2.67 mmol) in DMSO (15 ml). After stirring at 120°C for 3 h, the solvent is evaporated in vacuo at 60°C. The residue is washed with cold water to afford 0.42 g of crude product. Recrystallization from DMF affords 0.18 g of 9-fluoro-3-methyl-10-(1-piperazinyl)-7-oxo-2,3- dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, ethyl ester (20%) . Mp 255-260"C. Procedure 2 Preparation of 9-Fluoro-3-methyl-10-(3-amino-l- py- >lidinyl)-7-oxo-2,3-dihydro-7H-pyrido[l,2,3-de]- 1,4-benzoxazine-6-carboxylic acid. , Part A: 3-Acetoaminopyrrolidine (3.84 g, 30 mmol) is added to a solution of the difluOro ester (4.65 g, 15 mmol, Procedure 1, Part C) in pyridijie (55- l). After stirring at 60"C for 6 days, the solvent is evaporated in vacuo at 60"C. The residue is chromatographed over silic§ gel (550 g, 5% methanol/methylene chloride) to afford 2.92 g of 9-fluoro-3-methyl-10-(3-acetoamino-l-pyrrolidinyl)-7-oxo-2,3- dIhydro-7H-pyrido[l,2,3-de]-l,4-benoxazine-6-carboxylic acid, ethyl ester (47%). M.p. 217-220"C. Part B: 9-Fluoro-3-methyl-10-(3-acetoamino-l-pyrrolidinyl)-7-oxo-2,3- dihydro-7H-Ε ~ rido[l J 2,3-de]-1,4-benoxazine-6-carboxylic acid, ethyl ester (0.63 g, 1.5 mmol, Part A) is refluxed in 6N hydrochloric acid (HC1) (32 ml) . Aftex 45 min, the solvent is evaporated off under a stream of nitrogen. Water is added and the pH adjusted to 7.0 with IN sodium hydroxide. Evaporation of the solvent affords crude 9- fluoro-3-methyl-10-(3-amino-l-pyrrolidinyl)-7-oxo-2,3-dihydro-7H- pyrido[l,2,3-de]-l,4-benoxazine-6-carboxylic acid, which is not further purified and used in Example 3. F0RMULA SHEET R. -16- CHART 1 R-_«F or Cl References: 1. Chu, D. T. W.; Fernandas, P. B.; Clai o ne, A. K. ; Pihuleac, E; Nordeen, C. W.; Maleczka, R. E- Jr.; Pemet, A. G. J. Mβd. Chem. 1085, 28, 1558-1564. .CO a H 2. Chu, D. T. W Fernandas, P. B.; Claiborne, A. K.; Gracβy, E. H.; Pernβt, K Q. J. Uad. Chem. 1986, 29, 2363-2369. 3. Chu, D. T. W.; Femandes, P. B.; Maleczka, R. E., Jr.; Nordeen, C. W.; Pemet, A. Q. J. Mβd. Ch»m. 1987, 30, 504-509. C Λ "' 0O, j MM.-TββX '"CC σOO.. MMeβ 10 ., CHART 2 CHART 3 TABLE I Compound Cipro Compound (MIC) Assay Org. Code #2 #1 Org. Name 64 0.25 8 Acinetobacter ACAL12170 calcoaceticus 1 <0.008 0.25 Citrobacter freundll CFRE3507 10 2.0 10.0 Chlamydia trachomatis CTRA12366 1 0.015 0.5 Enterobacter cloacae ECL09382 2 0.015 1 Escherichia coli ECOL6674 2 0.015 0.5 Escherichia coli ECOL9451 2 0.015 1 Escherichia coli ECOL9855 1 0.015 0.5 Escherichia coli ECOL9952 4 0.03 1 Klebsiella pneumoniae KPNE12081 16 0.125 4 Pseudomonas aeruginosa PAER12120 32 0.5 16 Pseudomonas aeruginosa PAER6676 32 0.5 8 Pseudomonas aeruginosa PAER9191 2 0.015 0.5 Proteus penneri PPEN9679 4 0.25 0.5 Staphylococcus aureus SAUR6685 8 0.5 1 Staphylococcus aureus SAUR9213 4 0.5 0.5 Staphylococcus aureus SAUR9218 8 0.5 0.5 Staphylococcus aureus SAUR9271 2 0.125 0.5 Staphylococcus epi- SEPI30031 dermidis >64 0.5 8 Streptococcus faecalis SFAE9217 4 0.06 8 Serratia marcescens SMAR6888 16 0.25 2 Streptococcus SPNE41 pneumoniae 16 Streptococcus pyogenes SPY0152

Claims: CLAIMS A compound structurally represented by the formula (I) : and therapeutically acceptable salts thereof wherein R is hydrogen or hydroxyl; f R 2 is hydrogen or methyl; R4, R5, Rg, R7 are independently hydrogen, hydroxyl, halogen, C -C4 alkyl, ethenyl, ethynyl, C3-C cycloalkyl, fluoromethyl, di luoromethyl, difluoroethyl, trifluoromethyl, hydroxymethyl, Cχ-Cχg alkoxy methyl, phenoxymethyl, Cχ-C3 alkyl aminomethyl, C -C3) dialkyl aminomethyl, Cg-Cχ aryl, substituted aryl, heteroaryl or substituted heteroaryl containing at least one 0, N or S; Rg is hydrogen, hydroxyl, amine, C -C4 alkoxy or aryloxy, -SH, Gχ-Cg thioalkyl or thioaryl; R9 is C -C4 alkyl, Cg-Cχ 2 aryl, alkylaryl, heteroaryl, -(CH2) n - C0 2 -(GH )-.-Rχχ, wherein R x is hydrogen, hydroxyl, methyl alkyloxy, aryloxy or an amine, n is 0-4 and m is 0-4; Rχ 0 is hydrogen, - CH3 0> C 2 -C4 alkyl, Cg-Cχ 2 aryl, alkylaryl, heteroaryl, or acetyl, where o is 0 or 1; Rχ 2 is hydrogen CN, halogen, or R9; and Z is (CH 2 ) q where q is 0-2, CH-CH3 or C(CH 3 ) 2 . The compound of Claim 1 wherein R is hydroxy. The compound of Claim 2 wherein R2 is methyl. 4. The compound of Claim 2 wherein R2 is hydrogen. 5. The compound of Claim 6 wherein R3 is fluorine. 6. The compound of Claim 6 wherein R3 is hydrogen. 7. The compound of Claim 6 wherein R3 is primary amine (NH 2 ) . 8. The compound of Claim 6 wherein R3 is hydroxy. 9. The compound of Claim 1 wherein Rg is ethoxy and R9 is a carbomethoxy group. 10. The compound of Claim 1 wherein the carbon atom having the R5 group is bond to the nitrogen atom having the Rχo group, R o is -(CH3) 0 where o is 0, and Z is (CH2> q where q is 0. 11. The compound of Claim 10 which is (E)-2-[4-[6-carboxy-9-fluoro- 2,3-dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)-l,4-benzoxazin-10-yl]- 1-piperazinyl]-2-butendioic acid, 1,4-dimethyl ester or (E)-2-[4-[6- carboxy-9-fluoro-2, 3-dihydro-7-oxo-7H-pyrido(1,2,3-de) -1,4- benzoxazin-10-yl]-1-piperazinyl]-2-butendioic acid, 1,4-dimethyl ester. 12. The compound of Claim 1 wherein the carbon atom having the R5 group is bond to the carbon atom having the Rg group. 13. The compound of Claim 12 which is (E)-2-[4-[6-carboxy-9-fluoro- 2,3-dihydro-3-methyl-7-oxo-7H-pyrido(l,2,3-de)-l,4-benzoxazin-10-yl]- l-(3-amino-pyrrolidinyl)]-2-butendioic acid, 1,4-dimethyl ester or (E)-2-[4-[6-carboxy-9-fluoro-2,3-dihydro-7-oxo-7H-ρyrido(l,2,3-de)- l,4-benzoxazin-10-yl]-l-(3-amino-pyrrolidinyl)]-2-butendioic acid, 1,4-dimethyl ester. 14. A pharmaceutical composition containing an antibacterially effective amount of a compound according to Claim 1 in admixture with a pharmaceutical carrier. 15. The composition of Claim 14 containing from about 0.5 to about 90% by weight of said compound. 16. The composition of Claim 14 which is in unit dose form of tab¬ lets, pills, dragees, capsules, ampules or suppositories. 5 17. A method for treating bacterial Infection in animals including humans which comprises: administering to said animal an antibac¬ terially ef ective amount of a compound according to Claim 1. 10 18. The method of Claim 17 wherein said compound is administered orally ox pa enterally. 15 &

Inventors: BISAHA SHARON N, GAMMILL RONALD B, JUDGE THOMAS M, BISAHA, SHARON, N., GAMMILL, RONALD, B., JUDGE, THOMAS, M.
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1990
Main classification: C07D498
IPC codes: A61K31, A61P31, C07D498